- Lexaria’s patented DehydraTECH(TM) technology improves how APIs enter the bloodstream through the promotion of healthier oral ingestion methods while also increasing the effectiveness of fat-soluble active molecules
- As a disruptive technology, its impact has been felt by other players in its space, leading Lexaria to open its doors to partnering with industry experts and implementing the technology across many fields, including licensing the technology to Fortune 100 companies
- Lexaria will continue to make its technology accessible, improving the lives of people around the world
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has, since 2016, repeatedly demonstrated the potential of its patented technology, DehydraTECH(TM). The technology improves how active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting healthier oral ingestion methods while increasing the effectiveness of fat-soluble active molecules. With the help of this technology, Lexaria has explored potential treatment options for a variety of conditions, including hypertension, epilepsy, and even nicotine replacement.
The overall potential of DehydraTECH to be used to improve existing products or create new ones has seen its application in a growing range of consumer product formats, from topical applications to oral suspensions, registered drugs, nutraceuticals, consumer packaged goods, capsules, pills, and tablets. Furthermore, as a disruptive patented technology, its impact has been felt by other players in its space, leading to Lexaria opening its doors to partnering with Fortune 100 companies to implement the technology across many fields (https://ibn.fm/OqUtR).
Lexaria, through its licensing program, is making its technology accessible to more people, potentially improving the lives of hundreds of thousands, if not millions of people around the world. With the company having set its eyes on the commercial execution of its DehydraTECH technology for the new year, its licensing program will play a key role in achieving this end. Its management remains optimistic that, as its licensing program grows, more companies will come on board, bringing its technology closer to the masses.
Currently, Lexaria engages in strategic partnerships with third-party companies interested in exploring formulation opportunities with their specific APIs of interest. It also out-licenses its technology in exchange for up-front fees, milestone payments, and/or royalty payments, while offering dietary supplement GMP-grade intermediate formulations to corporate clients on a toll-processing basis.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.investorwire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.